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ABSTRACT 
Objective: Nephrotic syndrome defines as a disorder with a group of symptoms like proteinuria, hypoalbuminemia, hyperlipidemia, and 
edema. PMM2 encodes phosphomannosemutase protein enzyme involved in the synthesis of N-glycan.  
Methods: Different Insilico analysis tools: SIFT, PolyPhen, PROVEAN, SNPandGO, MetaSNP, PhDSNP, MutPred, I-Mutant, STRUM, PROCHECK-
Ramachandran, COACH and ConSurf, were used to check the effect of nsSNP on protein structure and function.  
Results: The genetic polymorphism in the PMM2 gene was retrieved from NCBI ClinVar and UniProtKB. Total 20 SNPs were predicted most 
significant and responsible for disease-causing and decrease protein stability.  
Conclusion: 
Keywords: nsSNP, PMM2, Nephrotic syndrome, Insilico analysis  
This study helps to discover disease-causing deleterious SNPs with different computational tools and gives information about potent SNPs.  
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) 
DOI: https://dx.doi.org/10.22159/ijpps.2021v13i7.41802. Journal homepage: https://innovareacademics.in/journals/index.php/ijpps.  
 
INTRODUCTION 
Nephrotic syndrome (NS) defines as a heterozygous group of 
disorders with clinical features like proteinuria, hypoalbuminemia, 
hyperlipidemia, and edema [1, 2]. The prevalence of nephrotic 
syndrome ranges from 12-16 per 100,001, and the annual impact in 
children ranges from 2-7 per 100,000 in India [3]. Based on steroid 
therapy, nephrotic syndrome is classified as steroid-sensitive 
nephrotic syndrome (SSNS) and steroid resistance nephrotic 
syndrome (SRNS) [4]. Aebi and his colleague found 
that Phosphomannosemutase (PMM2) is a causative gene 
responsible for steroid-resistant nephrotic syndrome [5]. 
Phosphomannosemutase is a homodimeric protein enzyme, which 
synthesizes a critical component for N-glycan. It is located on 
chromosome number 16 and carried out N or C glycosylation of 
protein [6]. This metabolic enzyme is activated by glucose 1-6 
bisphosphate and is involved in the isomerization of mannose 6 
phosphate into mannose 1 phosphate in the cytosol of the podocyte 
cell. The end product of the isomerization process is GDP-mannose 
and required for the biogenesis of N-glycans. Protein glycosylation is 
required for cell attachment to the glomerular basement membrane 
and podocyte morphology [7]. Several animal studies reveal the 
importance of glycosylation in nephron maturation. Membrane 
channels present in podocyte is excessively made up of n-linked 
glycosylated protein. It is also reported that these channels 
perpetuate the tubular structure of the nephron and affect the 
filtration process of the kidney [8]. Single nucleotide 
polymorphism (SNPs) is a DNA sequencing variation at a definite 
location in the genome [9]. It is an interchange of a single DNA 
building block and happens once in every 1,000 nucleotides in the 
genome. There are around 4 to 5 million SNPs in a person’s 
genome [10]. There were approximately 500,000 SNPs that fall in 
the coding region of the human genome. Recent studies show that 
about 50% of genetic mutation is due to nsSNP involved in various 
genetic diseases [11, 12]. There were>9 million SNPs reported in 
the public database [13]. To screen out these SNPs experimentally 
is time-consuming, costly, and very tedious. The computational 
analysis narrows down these SNPs and can be used as an 
alternative method. The Insilico analysis technique draws up the 
most affecting and significant nsSNP from the large dataset, and it 
is authentic and cost-effective [14].  
MATERIALS AND METHODS 
The genetic polymorphism in the 
Data mining  
PMM2 gene was retrieved from 
NCBI ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and 
UniProtKB (<https://www.uniprot.org/>). Swissport database was 
used for retrieving the protein sequence database of this gene. 
Functional analysis of prediction tools  
SIFT
Sorting Intolerant from Tolerant (SIFT) software is used to predict 
amino acid substitution on protein function [15]. It signifies a score 
ranging from 0.0 to 1.0 for evaluating change in an amino acid 
deleterious or tolerated. It is utilizing the rsID of SNPs as input 
queries from NCBI and SwissProt databases.  
 (https://sift.bii.a-star.edu.sg/www/)  
PolyPhen 
Polymorphism and phenotype (PolyPhen) work in a physical and 
comparative way to study the impact of amino acid substitution in 
the coding part of the gene. The predicted result was obtained in 
probability score classifying changes as ‘probably damaging,’ 
‘possibly damaging,’ and ‘benign’ [16]. 
(genetics.bwh.harvard.edu/pph2/) 
PROVEAN
Protein Variation Effect Analyzer (PROVEAN) is a sequence 
homology-based tool to estimate the nsSNP variation effect on 
protein function. These SNP variations are predicted according to 
the cutoff score of-2.5. If the cutoff score is<-2.5, it is “deleterious,” 
and the cutoff score is>-2.5, it is “neutral” [17]. 
 (provean.jcvi.org/index.php) 
SNPandGo (https://snps.biofold.org/snps-and-go/snpsandgo.html) 
SNP and Go is a tool used for the prediction of disease-related 
mutation. It is required the FASTA sequence of the protein as input 
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and gives the result as a disease (RI>5) or neutral (RI<5) based on RI 
(reliability index) [18]. 
Meta SNP
Meta SNP is used to predict a single nucleotide variation in protein 
sequence, and these prediction results are from different tools like 
PANTHER, PhD-SNP, SIFT, and SNAP [19]. The output value>0.5 is 
considered as a disease, and<0.5 is neutral. 
 (snps.biofold.org/meta.snp) 
PhD SNP (https://snps.biofold.org/phd-snp/phd-snp.html) 
Predictor of human Deleterious Single Nucleotide Polymorphisms 
(PhD-SNP) is a tool used to predict the effect of nsSNP on protein 
function. It interprets results like disease or neutral [20]. 
Mutpred (http://mutpred.mutdb.org/) 
Mutpred requires a FASTA file and amino acid variants as input. It 
gives the result in the form of the molecular mechanism and the 
probability of change in the protein structure and function [21]. 
Analysis of protein stability 
I-Mutant
I-Mutant is supporting vector-based software which predicts the 
effect of a single nucleotide change in protein stability. It is 
determining an increase or decrease in protein stability [22]. It 
results in free energy change (ddG) and the sign of prediction value 
as positive or negative. 
 (folding.biofold.org/i-mutant/I mutant2.0.html/) 
STRUM (https://zhanglab.ccmb.med.umich.edu/STRUM/) 
Structure-based prediction of protein stability change upon single-
point mutation (STRUM) is a tool that predicts change instability of a 
single nucleotide change. It gives the ddG value on change in a single 
nucleotide [23]. 
Protein modelling  
I-Tasser (https://zhanglab.ccmb.med.umich.edu/I-TASSER/)  
Iterative Threading Assembly Refinement (I-TASSER) is software 
used for protein 3D modeling from the FASTA sequence of the 
protein. It is generating five different models of the protein having 
different c-score. Based on the c-score, the appropriate model is 
selected. C-score is a confidence score in the range of-5 to 2. Higher 
the c-score, which means a high confidence level and vice-versa [24]. 
Discovery studio (http://accelrys.com/products/collaborative-
science/biovia-discovery-studio) 
Discovery Studio is software used for protein modeling and its 
targets. It is used for generating the 3D structure of the model from 




Based on the c-score of the model, the PDB structure was selected. 
This model was verified by the Ramachandran plot using the 
PROCHECK server. A two-dimensional plot is used to distribute 
amino acids in the different conformation of the ψ and φ angles [14]. 
Identification of ligand binding site 
COACH (https://zhanglab.ccmb.med.umich.edu/COACH/) 
The ligand-binding site of PMM2 protein was estimated by using the 
COACH server. It is a free software used for the prediction of the 
ligand-binding site of PMM2 protein. COACH is a meta-server-based 
software and works on different methods like S-SITE and TM-SITE. 









 protein, the ConSurf web-server was used. After 
submitting the FASTA sequence in the ConSurf, position-specific 
conservation scores were calculated using an empirical Bayesian 
algorithm. These conservation scores having well-defined scales of 
nine grades, i.e., 1-9. A score near 9 represent more conserved, and 
near one, it means variable. 
 
Fig. 1: Diagrammatic representation of computational tools used for Insilico analysis of the PMM2 gene 
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SNPs for the PMM2 gene were retrieved from uniport and ClinVar. In 
ClinVar, there were 356 SNPs in which 15 frameshift variants, 91 
missense variants, 12 nonsense variants, 16 splice region variants, 
and 80 in the UTR region. We have selected only missense variants 
for this study. 
In this study total of seven functional analysis tools (fig. 1) were 
used. These tools included: SIFT, PolyPhen, PROVEAN, SNPandGO, 
MetaSNP, PhDSNP, and MutPred. According to SIFT results, a total of 
53 variants were identified as affect protein function, and others 
were tolerated. This prediction was based on the SIFT prediction 
score. All 53 variants were further analyzed by PolyPhen, PROVEAN, 
SNP and GO, METASNP, PhDSNP, and MutPred tools. PolyPhen 
predicted variants as probably damaging, possibly damaging and 
benign. Out of 53 variants, 43 variants were predicted as probably 
damaging, 17 were possibly damaging, and 16 were benign. PROVEAN 
predicts SNPs either deleterious or neutral. Out of 53 variants, 52 were 
predicted as deleterious by SNP and GO and 49 by MetaSNP. PhDSNP 
is a very accurate SVM-based prediction method. It revealed only 34 
SNPs were diseased ones, and the rest 22 SNPs were neutral. MutPred 
further validated these 34 variants. Mutpred predicts the association 
between deleterious variation and disease condition. These SNPs were 
predicted as loss of strand, altered stability, an altered transmembrane 
protein, and loss of Acetylation. Mutpred predicts a deleterious effect 
of these variants, given in the table (table 1). 
Functional analysis tools 
 
Table 1: nsSNP predicted to be functionally significant in PMM2 protein using functional analysis tools 
rsID Amino acid 
change 





rs758340382 R21W APF PD Deleterious D D D Loss of Acetylation 
rs398123312 L32R APF PD Deleterious D D D Loss of Acetylation; Altered Stability 
rs755402538 G42R APF PD Deleterious D D D Altered DNA binding 
rs104894534 V44A APF PD Deleterious D D D Altered Transmembrane protein; Altered Stability 
rs770458492 L104V APF PD Deleterious D D D - 
rs387906824 Y106K APF PD Deleterious D D D Gain of Acetylation; Altered Transmembrane protein 
rs80338700 P113L APF PD Deleterious D D D Altered Transmembrane protein 
rs104894530 G117R APF PD Deleterious D D D Loss of Strand; Altered Transmembrane protein 
rs1057517110 F119L APF PD Deleterious D D D Loss of Strand 
rs368582085 I120T APF PD Deleterious D D D Loss of Strand; Altered Stability 
rs190521996 F157S APF PD Deleterious D D D Loss of Acetylation; Altered Stability 
rs941830625 G175R APF PD Deleterious D D D Altered Metal-binding; Gain of ADP-ribosylation 
rs780581250 F183S APF PD Deleterious D D D Altered Transmembrane protein; Altered Stability; Loss of 
Proteolytic cleavage 
rs80338704 D188G APF PD Deleterious D D D Gain of Acetylation; Altered DNA binding; Altered 
Transmembrane protein 
rs532870929 F207S APF PD Deleterious D D D Altered Stability; Loss of Acetylation; Loss of Allosteric site 
rs398123309 G208A APF PD Deleterious D D D Loss of Allosteric site; Altered Transmembrane protein 
rs78290141 N216S APF PD Deleterious D D D Altered Metal-binding; Altered Transmembrane protein 
rs752614554 D217E APF PD Deleterious D D D Altered Metal-binding; Altered Transmembrane protein 
rs80338706 T226S APF PD Deleterious D D D - 
rs558826439 G228R APF PD Deleterious D D D Altered Metal binding 
rs80338708 V231M APF PD Deleterious D D D Altered Ordered interface; Loss of Relative solvent 
accessibility 
rs80338708 T237R APF PD Deleterious D D D Loss of Relative solvent accessibility; Altered Metal 
binding 
APF: Affect protein function, PD: Probably damaging, D: Disease 
 
Table 2: Stability prediction analysis of PMM2 protein by I-Mutant and STRUM 
rsID Amino acid change I-mutant strum 
Stability Free energy change ddG 
rs758340382 R21W Decreases -0.21 -0.42 
rs398123312 L32R Decreases -1.05 -4.58 
rs755402538 G42R Decreases -1.81 -1.92 
rs104894534 V44A Decreases -2.27 -1.82 
rs770458492 L104V Decreases -0.58 -0.38 
rs387906824 Y106K Decreases -0.57 -1.23 
rs80338700 P113L Decreases -1.02 -0.2 
rs104894530 G117R Decreases -1.83 -1.23 
rs1057517110 F119L Decreases -2.34 -0.99 
rs368582085 I120T Decreases -1.26 -1.71 
rs190521996 F157S Decreases -2.24 -2.42 
rs941830625 G175R Decreases -2.36 -0.39 
rs780581250 F183S Decreases -2.99 -2.31 
rs80338704 D188G Decreases -2.07 -0.53 
rs532870929 F207S Decreases -3.74 -2.25 
rs398123309 G208A Decreases -2.18 -1.23 
rs78290141 N216S Decreases -0.74 -0.9 
rs80338706 T226S Decreases -0.23 -1.0 
rs558826439 G228R Decreases -1.39 -0.4 
rs80338708 V231M Decreases -2.26 -1.51 
 
Mistry et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 7, 87-93 
 
90 
Analysis of protein stability 
I-Mutant and STRUM were used to predict the variant's stability. I-
Mutant indicates RI and free energy change value for nsSNP. STRUM 
is also giving the ddG (free energy change) value for a single 
nucleotide change. Out of 22 SNPs, 20 SNPs show decreased protein 
stability for both I-Mutant and STRUM. The result of I-Mutant and 
STRUM is shown in the table (table 2). 
Protein modeling  
The 3D structure of the protein was derived from I-Tasser. The 3D 
structure of PMM2 protein was generated by submitting the FASTA 
sequence of protein after changing its amino acid to its altered 
amino acid. I-Tasser generates a 3D model of the protein and based 
on the c-score, the most stable structure was selected.  
Structure validation  
Ramachandran plot (fig. 2.) is used to validate the structural stability 
of the protein. Out of all the amino acids, 186 amino acids (85.7%) 
were found to be in the favored region, 28 (12.9%) amino acids 
were in the additional allowed region, 3(1.4%) were in generously 
allowed regions, and 0% were in the disallowed region. From the 




Fig. 2: Ramachandran plot of modeled PMM2 protein 
 
Identification of ligand-binding site  
The most stable structure of the protein is used to determine the 
ligand-binding site of the enzyme. Those SNPs present in the Ligand 
binding site of PMM2 protein were Arg21, Gly175, Asn216, Thr226, 
and Gly228. The Asn216 and Arg21 were involved in the binding of 
Mannose 6 phosphate and Mannose 1 phosphate, which are the 
substrate of protein glycosylation. These five binding sites are 
shown in Fig.3. by using pymol. Table 3 shows the results of the 
COACH server. 
Phylogenic analysis  
ConSurf  
Conserved and variable regions of PMM2 protein were predicted by 
the ConSurf server (table 3). The R21W, G175R and N216S have a 
conservation score of 9 and T226S and G228R have 8. All the amino 
acid residues fall in conserved regions, showing more possibilities to 
alter the protein structure [21]. The 3D structure and ligand-binding 
sites present in different conserved regions of PMM2 protein 
mentioned in fig. 4. 
 
Fig. 3: Ligand binding sites within PMM2 protein 
 
Table 3: Prediction of ligand binding sites and phylogenetic conservation within PMM2 protein 
rsID Amino acid change Ligand name (coach) ConSurf conservation score 
rs758340382 R21W M1P 9/conserved 
rs941830625 G175R M6P 9/conserved 
rs78290141 N216S PO4, M6P, MG 9/conserved 
rs80338706 T226S GLY, MG 8/conserved 
rs558826439 G228R GLY, MG 8/conserved 
M1P: mannose 1 phosphate, M6P: mannose 1 phosphate, PO4: phosphate, MG: magnesium, GLY: glycine 
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Fig. 4: (a) Conserved region in PMM2 protein (b) Ligand binding sites in different conserved regions of PMM2 gene 
 
DISCUSSION 
PMM2 is a metabolic protein and is mainly involved in the 
glycosylation of protein. Protein glycosylation requires for normal 
structure and function of protein which are involved in kidney 
morphogenesis. Glycoproteins are also required in cell adhesion in 
the basement membrane and cell migration [27]. In vitro study 
reveals that glycosylation also requires for functional growth of 
nephron. SNPs are genetic variations involved in various genetic 
diseases. Single nucleotide polymorphisms are linked to phenotypic 
and genotypic traits of individuals. Monogenic and inherited 
diseases are also correlated with single nucleotide change 
[28]. PMM2 gene variants have also been linked to other diseases 
like a congenital disorder of glycosylation [29]. Not all nsSNP have a 
deleterious effect on protein function, so different bioinformatic 
tools were used to identify the effect of these SNPs. These tools are 
SIFT, PolyPhen, PROVEAN, SNPandGO, MetaSNP, PhDSNP, MutPred, 
and I-Mutant. After functional analysis, a total of 22 variants were 
found to be deleterious (table 1) in human PMM2 protein. Despite p. 
Thr237Arg and p. Asp217Glu variants, all other SNPs have 
decreased the stability of the protein. Arg21, Gly175, Asn216, 
Thr226, and Gly228 were involved in the enzyme’s ligand-binding 
site, and they are conserved and have a structural and functional 
effect on PMM2 protein by the ConSurf server (table 3). Single 
nucleotide change in the ligand-binding site may affect interaction 
and interfere in the normal function of the enzyme and affect its 
stability. Several genetic studies reveal the role of the PMM2 gene in 
a disease condition. Sarah and his colleagues found two mutations 
(p. Arg141His and p. Val231Met) in patients having a congenital 
disorder of glycosylation-Ia [30]. Two distinct variants (p. 
Arg141His and p. Arg215Leu) of the PMM2 gene were reported in 
the Argentinean population [31]. Different PMM2 variants were 
enlisted according to the Insilico analytical study of the congenital 
disorder of glycosylation, i.e., p. Asp65Tyr, p. Ile132Asn, p. 
Ile132Thr, and p. Phe183Ser [32]. Casado and his team discovered 
two mutations in two different patients with a congenital 
glycosylation disorder; they were p. Cys241Ser, p. Arg123Gln and p. 
Gly722Cys, p. Phe157Ser, respectively [29]. Several variants were 
also characterized in a proteolytic expression system. They were 
affecting protein stability (p. Arg123Gln and p. Arg141His). These 
two variants were disrupting dimer interface (p. Pro113Leu and p. 
Thr118Ser) and few others involved in misfolding changes (p. 
Leu32Arg, p. Val44Ala, p. Asp65Tyr, p. Phe157Ser, p. Pro184Thr, p. 
Phe207Ser, p. Thr237Met, and p. Cys241Ser) [33]. Patricia and his 
colleague found nine different mutations in the PMM2 gene. Out of 
nine, six mutations (p. Val44Ala, p. Asp65Tyr, p. Arg162Trp, p. 
Thr237Met, p. Phe207Ser, and p. Cys241Ser) retained some residual 
activity of the protein. Two of them (p. Arg123Gln, and p. 
Arg141His) affected protein folding and catalytic property 
of PMM2 protein. Mutation position p. Pro113Leu is associated with 
the dimerization of PMM2 protein [34]. A study on hyperinsulinemic 
hypoglycemia and congenital polycystic kidney disease revealed 
promoter region mutation (p. Gly167Thr) on the PMM2 gene [35]. 
This study helps to understand the effect of nsSNP on PMM2 protein 
and suggesting that computer-based analysis help to select SNPs 
responsible for altering protein and affecting protein phenotype. 
This Insilico analysis is helpful for further laboratory experiments, 
i.e., these variants are further validated by lab-based experiments. 
CONCLUSION 
PMM2 protein is mainly involved in the synthesis of membrane 
channels of the nephron. In this study, nsSNP of the PMM2 gene was 
determined by various bioinformatics tools. Total twenty significant 
SNPs were predicted as disease-causing. Among the most significant 
SNPs, Arg21, Gly175, Asn216, Thr226, and Gly228 were associated 
Mistry et al. 
Int J Pharm Pharm Sci, Vol 13, Issue 7, 87-93 
 
92 
with the protein's ligand-binding site. These SNPs can affect protein 
and are considered vital components that are causing diseases 
related to PMM2 malfunction and help in drug discovery. This 
variation has been utilized for diagnosis as well as a therapeutic 
target for genetic diseases. Bioinformatic outcomes may be helpful 
for further lab-based experiments to study the effect of 
polymorphism on protein function.  
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